anti hypertensive module
Post on 06-Apr-2018
230 Views
Preview:
TRANSCRIPT
-
8/2/2019 Anti Hypertensive Module
1/71
Antihypertensive Drugs
Dr/Azza Baraka
Prof of Clinical Pharmacology
Faculty of Medicine
Alexandria University
-
8/2/2019 Anti Hypertensive Module
2/71
Definition
Elevation of ABP > 140/90 mm Hg. Can be caused by:
primary or essential hypertension
The pathophysiology might be:
vascular resistance cardiac output
arterial compliance.Primary Hypertension cannot be cured, but it can be controlled
Secondary hypertension, e.g. pheochromocytoma,
cured by treating cause
-
8/2/2019 Anti Hypertensive Module
3/71
Classification of blood pressure levels
Category Systolic (mmHg) Diastolic (mmHg)
Normal 100
Isolated systolic hypertension appears to resultfrom an increased stroke volume and/oraortic stiffness( arterial compliance).
-
8/2/2019 Anti Hypertensive Module
4/71
Treatment Goals
Short-term goal of antihypertensive therapy:
Reduce blood pressure
Long-term goal of antihypertensive therapy:
Reduce mortality due to hypertension-induced
end organ damage:
Encephalopathy
LVH -Congestive heart failure
Nephropathy
-
8/2/2019 Anti Hypertensive Module
5/71
ABP=COPX PVR=SV X HR X PVR
Modulators of COP SV( blood volume, venous return, Contractility).
Heart Rate . Modulators of PVR
- Diameter of peripheral arterioles
To BP:
1. LV systolic performance:negative inotropes andchronotropes
2. blood volume3. venous tone and thus
venous return.4. PVR
-
8/2/2019 Anti Hypertensive Module
6/71
Blood pressure treatment goals
Systolic BP be reduced to less than 140 mmHgand diastolic BP to less than 90 mmHg in the
general population of patients.
Lower systolic BP goal (
-
8/2/2019 Anti Hypertensive Module
7/71
Management of hypertension
Non pharmacological therapy1. Sodium Restriction2. DASH high fruit , vegetable, whole grains &
low fat dairy foods
Pharmacological therapy
ABCDEs
ACE inhibitors and AT-II antagonists
-adrenoceptor blockers Ca2+ channelblockers
Diuretics Extras: Vasodilators, centrally acting symptholytics,..
-
8/2/2019 Anti Hypertensive Module
8/71
Considerations for choice of initial
antihypertensive monotherapy
Target end organ damage
Coexisting : cardiovascular disease,
renal disease or diabetes.
Renin status (Age & Race)
Presence or absence of side effects
to the selected drug.
-
8/2/2019 Anti Hypertensive Module
9/71
Ideal antihypertensive drug
(1) decrease BP
(2) couple the antihypertensive effectiveness withno harmful side effects
(3) provide greater protection against the organdamage associated with hypertension.
(4) provide inhibition of the counter-regulatorymechanisms (SNS & Na retention). i.e. doesnot cause reflex tachycardia nor fluid retention
-
8/2/2019 Anti Hypertensive Module
10/71
First line antihypertensive drugs (A B C D )
Hypertension (HTN) can be classified as:
High renin hypertension (younger55 or black)Therefore HTN treated initially with one of two
categories of AHDs:
1-those that inhibit RAS, namely ACE inhibitors(A) and beta-blockers (B)
2- those that do not, namely calcium channel
blockers (C) and diuretics (D)
-
8/2/2019 Anti Hypertensive Module
11/71
Diuretics
Indications
Drug of choice for uncomplicated mild-
moderate HTN in black & elderly patients(low renin)
Drug of choice for isolated systolichypertension
Synergistic with other AHDs in severeHTN
-
8/2/2019 Anti Hypertensive Module
12/71
AT start of their use, they lower BP bycausing diuresis leading to a fall in plasmavolume & COP .
After chronic use they cause a reduction in
BP by VD PVR, likely related to shift ofsodium from vascular smooth muscle wall toECF.
In low doses, their side effects seem to beminimized.
Low dose Thiazide diuretics
-
8/2/2019 Anti Hypertensive Module
13/71
Advantages
Well tolerated with few side effects.
Have synergistic effect when added toother AHDs .
Relatively inexpensive.
Disadvantages Metabolic adverse effects
(hypokalemia,hypercalcemia etc); are
dose- related.Lose their effectiveness in renal insufficiency.
-
8/2/2019 Anti Hypertensive Module
14/71
Loop diuretics
Loop diuretics are used for hypertension associated
with renal insufficiency.
-
8/2/2019 Anti Hypertensive Module
15/71
-Adrenoceptor blockers Drugs of 1st choice for uncomplicated HTN in high
renin patients (
-
8/2/2019 Anti Hypertensive Module
16/71
-Adrenoceptor blockers Mechanism of blood pressure reduction
Reduction of HR and myocardial contractility Inhibition of renin release
Inhibition of CNS sympathetic outflow
-
8/2/2019 Anti Hypertensive Module
17/71
Types of-blockers
Non cardioselective
Cardioselective
Beta blockers with vasodilatory properties(Labetalol & Carvedilol).
All -blockers are EQUALLY effective in
reducing blood pressure but differ in sideeffects.
-
8/2/2019 Anti Hypertensive Module
18/71
Diuretics & beta blockers are notpreferred to be used as AHDs in
hypertensive diabetic patients.
-
8/2/2019 Anti Hypertensive Module
19/71
Drugs Interacting With the RAS
ACE inhibitors
ATII antagonists
-
8/2/2019 Anti Hypertensive Module
20/71
Physiology of Renin-
Angiotensin System
-
8/2/2019 Anti Hypertensive Module
21/71
Physiological Effects of AII:
1.
VC of arteries & veins2. + aldosterone secretion
3. + renal sodium resorption & RBF, glomerular capillary pressure
4. + LVH
5. Facilitate adrenergic transmission
-
8/2/2019 Anti Hypertensive Module
22/71
Mechanism of action of ACEIs
Inhibition of ACE
Angiotensin II
BradykininVD
AngiotensinII
Angiotensin I
BradykininInactive
product
CE
-
8/2/2019 Anti Hypertensive Module
23/71
echanism ofBP by ACEIs1. aldosterone release salt & water
retention
2. VD of both arterioles & veins
3. Decrease adrenergic activity
-
8/2/2019 Anti Hypertensive Module
24/71
Therapeutic Uses in Hypertension
Drug of choice in high renin hypertension (whiteor
-
8/2/2019 Anti Hypertensive Module
25/71
Advantages of ACE inhibitors &
ARBs as AHDs1. A & V dilation with no reflex
tachycardia & no fluid retention
2. Most effective AHD in LVH(remodeling).
3. Intraglomerular pressure so effective in
diabetic nephropathy.
-
8/2/2019 Anti Hypertensive Module
26/71
Types of ACE Inhibitors
Active molecules: Captopril,Lisinopril, Enalaprilat
Prodrugs: The remainder of ACEinhibitors, e.g. enalapril, lisinopril,..
All metabolized by liver except lisinoprilby kidney.
Ad ff t f ACEI
-
8/2/2019 Anti Hypertensive Module
27/71
Adverse effects of ACEIs
1. Hypotension esp in volume depleted individuals
2. Cough : dt accumulation of BK in the lung
It is a dry cough. Occur in 30% of patients
3. Angioedema: dt BK
4. Teratogenicity
5. Hyperkalemia due to aldosterone
-
8/2/2019 Anti Hypertensive Module
28/71
Contra-indication for ACEIs1. Pregnancy2. Bilateral renal artery stenosis
3. Low blood pressure: SBP< 90mmHg
4. Hyperkalemia
-
8/2/2019 Anti Hypertensive Module
29/71
Angiotensin II R antagonists
Block angiotensin II receptors subtype 1
Differences vs ACEIs:
ARBs do not affect BK system: No cough and No
angioedema
-
8/2/2019 Anti Hypertensive Module
30/71
Ca2+ Channel Blockers
Indications in hypertension:
Drug of choice in isolated systolic hypertension in
elderly if diuretic is contraindicated . low renin hypertension when diuretics are
contraindicated.
Hypertension with diabetes in presence ofcontraindication to ACEIs & ARBs
-
8/2/2019 Anti Hypertensive Module
31/71
CCBs Mechanism of antihypertensive
actionBlock calcium channels in the arterial smooth
muscles VDPVR
Block calcium channels in the cardiacmusclesHR &force of contraction
Types;
Dihydropyridines, e.g. nifedipine, amlodipine
Non dihydropyridines, e.g. verapamil & diltiazem
-
8/2/2019 Anti Hypertensive Module
32/71
DihydropyridinesNifedipine
Non dihydropyridinesDiltiazem Verapamil
>> selective action on vascular CC >> selective action on cardiac CC
Arterial vasodilation++++
minimal net effect on cardiac contractility
Reflex tachycardia
Arterial vasodilation ++
-ve inotropic
Heart rate
Therefore VD with no reflex tachycardia
Uses :Essential hypertension
Angina pectoris
Uses :Essential hypertension
Angina pectoris
Supraventricular arrhythmia
Side effects:
1.Hypotension
2.Reflex tachycardia
3.Flushing
4.Ankle oedema
Side effects:
1.Hypotension
2.Bradycardia
Contra-indication: tachyarrhythmia
Can be safely combined with BB
Contra-indication: HF & heart block, severe
bradycardia
Combination with BB is not safe
-
8/2/2019 Anti Hypertensive Module
33/71
Vasodilators
1-Arteriolar: Hydralazine
Never used as first choice in HTN; Try in severe hypertension
as part of a multidrug regimen or in pregnancy.
Adverse effects:
1. Reflex tachycardia
2. Salt & water retention
Should be combined with diuretic & beta blocker
-
8/2/2019 Anti Hypertensive Module
34/71
2- Vasodilators to A&V: Sodium nitroprusside
Acts by releasing NO that increase cGMPthat dilate A & V.
Clinical use:
Emergency treatment of severe hypertension
Given by IV infusion( it has a very short t )
Adverse effects
Hypotension,Reflex tachycardia
Prolonged infusion ( more than 72 hrs)Cyanide & Thiocyanate accumulation
-
8/2/2019 Anti Hypertensive Module
35/71
Centrally acting AHDs
Alpha methyl dopa: Preferredantihypertensive drug for
hypertension in pregnancy
-
8/2/2019 Anti Hypertensive Module
36/71
Preferred antihypertensive drugs forhypertension in pregnancy
Agent Com
Methyldopa Preferred on the basis of long-term follow-up
studies supporting safety
labetalol Increasingly preferred to
methyldopa because ofreduced side effects
CCB(nifedipine ) intermediate-releasetablets and slow-release
tablets could be used
-
8/2/2019 Anti Hypertensive Module
37/71
AHDs that do not cause reflex tachycardia:1-Beta blockers2-CCB(Non dihydropyridines)3-ACE inhibitors & ARBs AHDs that do not cause fluid retention:1. Diuretics
2. CCB(Non dihydropyridines)3. ACE inhibitors & ARBs
-
8/2/2019 Anti Hypertensive Module
38/71
AHDs used or CI in certain disease: Diabetes Beta-blockers and diuretics are CI.
ACE inhibitors & ARBs are of choice.
IHD Beta-blockers are used & offer a mortalitybenefit
LVH: ACE inhibitors & ARBs are used. Beta-blockers are used if ACE inhibitors & ARBs are CI.
Bronchial Asthma Beta-blockers CI. Renal Artery Stenosis (bilateral vs. unilateral)
ACE inhibitor orARBs are contraindicated.
Pregnancy ACE inhibitors and ARBs arecontraindicated, use methyl dopa.
-
8/2/2019 Anti Hypertensive Module
39/71
Hypertensive emergency vs hypertensive urgencyEmergency Urgency
Severe elevation in blood pressure (>
180/120 mm Hg)
Severe elevation in blood
pressure (> 180/120 mm Hg)
End organ damage without end organ damage
Treatment:
Parenteral Drugs Patients should always be managed in
an ICU to allow continuous monitoringof BP
Reducing mean B P by 10% during 1sthr and 15% within next 2-3hrs
E.g. Sodium nitroprusside ( IV infusion),
Treatment:
Oral antihypertensive.
Drugs Can be given in aclosely monitored outpatient
setting.
BP should not be lowered
more than 25% within the 1st
24hrs
Sublingual captopril,
-
8/2/2019 Anti Hypertensive Module
40/71
What could happen to this patient if he does notreceive treatment?
Case Study
Multiple PossibilitiesHeart: hypertrophy; myocardial infarction; heart failure
Brain: strokeKidney: renal failure; chronic kidney diseaseVasculature: peripheral vascular disease
Eye: retinopathy
-
8/2/2019 Anti Hypertensive Module
41/71
What is the most appropriate treatment forthis patient?
Case Study
-Assess BP for a third time in one month
-If elevated, suggest lifestyle change (exercise,diet etc)
-If unsuccessful, use diuretics (cheap& effective)
-
8/2/2019 Anti Hypertensive Module
42/71
If the patient develops diabetes would
you continue with diuretics?
-Use ACE inhibitors which are
renoprotective
drugs for hypertension in
-
8/2/2019 Anti Hypertensive Module
43/71
drugs for hypertension inpregnancy
Agent Com
IV labetalol Best avoided in women with asthmaor heart failure. Neonatology
should be informed, as parenterallabetalol may cause neonatal
bradycardia
IV hydralazine May increase the risk of maternal
hypotension
Oral nifedipine intermediate-releasetablets could be used
Agents used for Severe Hypertension(BP of >160/110 mmHg g)
-
8/2/2019 Anti Hypertensive Module
44/71
Drugs that cause Vasodilation and decreaseheart rate:
1-Central alpha 2 agonists,e.g. clonidine
2-Calcium channel blockers(non-dihydropyridines)
3-Combined alpha and beta blockers, e.g.
labetalol, carvedilol. Drugs that cause Vasodilation and that do
not affect heart rate: ACE inhibitors & ARBs
-
8/2/2019 Anti Hypertensive Module
45/71
Particular classes of antihypertensivetherapy have beneficial actions beyond
blood pressure and studies haveevaluated differences in cardiovascularprotection among classes. The LIFEand HOPE studies showed between-
class differences that may be due toeffects other than blood pressure-lowering .
-
8/2/2019 Anti Hypertensive Module
46/71
Drug therapy causes peripheral edema by two opposingmechanisms. First, as with nonspecific vasodilators such ashydralazine and minoxidil, sodium retention can be of sufficientmagnitude to cause edema. The sodium retention caused by thesedrugs is highly dose-dependent and when present almost always
requires diuretic therapy because it seldom remits spontaneouslyunless the dose of the nonspecific vasodilator is reduced [.4] Otherantihypertensives such as blockers, central agonists, andperipheral blockers can also be associated with the development ofsome peripheral edema, particularly when given in high doses [.5]Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are rarely associated with peripheraledema. If peripheral edema develops from the use of a calciumchannel blocker (CCB), it is not on the basis of salt and waterretention because this drug class is intrinsically natriuretic [.6]
-
8/2/2019 Anti Hypertensive Module
47/71
Another strategy useful for the resolution ofCCB-related edema is providing a
venodilator drug as a means to reducing thevenous hypertension that characterizes thisphenomenon[.13,37-39]Several drug
classes have relevant venodilating potential
and, in addition, can further reduce bloodpressure. This includes ACE inhibitors, ARBs,
and nitrates[.40]
-
8/2/2019 Anti Hypertensive Module
48/71
Four generations of dihydropyridines are now available. The first-generation(nicardipine) agents have proven efficacy against hypertension. However,because of their short duration and rapid onset of vasodilator action, thesedrugs were more likely to be associated with adverse effects. Thepharmaceutical industry responded to this problem by designing slow-releasepreparations of the short-acting drugs. These new preparations (second
generation) allowed better control of the therapeutic effect and a reduction insome adverse effects. Pharmacodynamic innovation with regard to thedihydropyridines began with the third-generation agents (amlodipine,nitrendipine). These drugs exhibit more stable pharmacokinetics, are lesscardioselective and, consequently, well tolerated in patients with heart failure.Highly lipophilic dihydropyridines are now available (lercanidipine, lacidipine).These fourth-generation agents provide a real degree of therapeutic comfortin terms of stable activity, a reduction in adverse effects and a broad
therapeutic spectrum, especially in myocardial ischaemia and potentially incongestive heart failure.
-
8/2/2019 Anti Hypertensive Module
49/71
Why we treatarrhythmia????????
Arrhythmias may require treatment becauserhythms that are too rapid, too slow, or
asynchronous can reduce cardiac output. Some
arrhythmias can precipitate more serious or evenlethal rhythm disturbanceseg, early prematureventricular depolarizations can precipitate
ventricular fibrillation. In such patients,antiarrhythmic drugs may be lifesaving. On the
other hand, the hazards of antiarrhythmic drugsand in particular the fact that they can precipitatelethal arrhythmias in some patientshas led to a
reevaluation of their relative risks and benefits. Ingeneral, treatment of asymptomatic or minimally
symptomatic arrhythmias should be avoided for this
-
8/2/2019 Anti Hypertensive Module
50/71
the P wave is generated by atrial depolarization, theQRS by ventricular muscle depolarization, and the T
wave by ventricular repolarization. Thus, the PR
interval is a measure of conduction time fromatrium to ventricle, and the QRS duration indicatesthe time required for all of the ventricular cells to
be activated (ie, the intraventricular conductiontime). The QT interval reflects the duration of the
ventricular action potential.Arrhythmias consist of cardiac depolarizations that
that deviate from the above description in one ormore aspects ie, there is an abnormality in the siteof origin of the impulse, its rate or regularity, or its
conduction
-
8/2/2019 Anti Hypertensive Module
51/71
Reduce LV systolic performance : negative inotropesbetablocker and calcium channel blockers (verapamil,diltiazem)).
Reduce blood volume : diuretics Reduce venous tone and thus venous return: Central
sympatholytics such as clonidine act to reduce overallsympathetic tone.
Reduce arterial tone (i.e. resistance) : Effective arterialdilators include angiotensin converting enzyme inhibitors ,
angiotensin receptor blockers , calcium channel blockers(nifedipine, amlodipine), potassium channel openers(minoxidil), nitric oxide donors (nitroprusside), alpha1blockers (prazosin, terazosin, doxazosin), and mixed alphaand beta-blockers (labetalol)
-
8/2/2019 Anti Hypertensive Module
52/71
Hypertension damages blood vessel walls. The prolongedvasoconstriction and high pressure within the vessels causesarterial smooth muscle to thicken to withstand the stress.Eventually, the tunica intima and tunica media thicken and
narrow the lumen. At this point, the vessels are permanentlynarrowed.
After the vessels are injured, biochemical mediators(histamines, leukotrienes, and prostaglandins) are released toincrease the endothelium's permeability. As permeability
increases, sodium, calcium, water, plasma proteins enter thevessel, causing further thickening and increasing theresponsiveness to stimuli, which causes vasoconstriction.
-
8/2/2019 Anti Hypertensive Module
53/71
Effects of Different Classes of Antihypertensive Drugs on SNS(Centrally and Peripherally Mediated Effects
-
8/2/2019 Anti Hypertensive Module
54/71
This nitrovasodilator selectivity, however,probably reflects the need for most organicnitrovasodilator drugs, such as glyceryl trinitrateor the isosorbide nitrates, to undergo
metabolic conversion to provide the activeprinciple, nitric oxide, and veins seem betterendowed with this metabolic pathway thanarteries (while platelets seem to lack itentirely)' 61-these considerations do not apply
to molsidomine, SIN- 1, or sodium nitroprussidewhich are sources of nitric oxide thatdo not depend on this metabolic step.also veins produce little No
so respond more to exogenous NO produced by nitrites
-
8/2/2019 Anti Hypertensive Module
55/71
Adverse Effects
Bradycardia
Heart failure Bronchospasm
Coldness of extremities
Withdrawal effects
Glucose metabolism
-
8/2/2019 Anti Hypertensive Module
56/71
5.Adverse Effects (Cont)
CNS effects Pregnancy
Rise in plasma triglyceride concentration;
decrease in HDL cholesterol Drug interactions: NSAID'S - can blunt effect of-blockers
Epinephrine - causes severe hypertension inpresence of-blockade
Ca2+channel blockers Conduction effects onheart are additive with blockers.
-
8/2/2019 Anti Hypertensive Module
57/71
Adverse Effects Unique toMethyldopa:
Heart block (methyldopa)
Immunological changes: positive
Coombs test (20% after 1 year), lupuslike syndrome, leukopenia, red-cellaplasia
Altered liver function 5%Avoid in depression
-
8/2/2019 Anti Hypertensive Module
58/71
Centrally acting imidazoline I(1)-receptor agonists
Such as moxonidine and rilmenidine induce peripheral
sympathoinhibition via the stimulation of I(1)-receptors in the medulla. Because of a rather weakaffinity for alpha(2)-adrenoceptors, the use of theseagents is associated with a lower incidence of adversereactions.
Although available data indicate that I(1)-receptoragonists are effective in patients with hypertension,
comparative data versus agents such as beta-blockers,diuretics, calcium channel antagonists and ACEinhibitors are required to establish their position in thetreatment of hypertension.
-
8/2/2019 Anti Hypertensive Module
59/71
Early after-depolarizations involve the reactivation of L-type Ca2+channelsduring prolonged repolarization, whereas DADs appear when Ca2+is released
from the sarcoplasmic reticulum (SR) during diastole. Diastolic Ca2+risesactivate the Na+Ca2+exchanger (NCX), which carries three Na+ions into
the cell in exchange for each Ca2+transported out, causing net inwardmovement of one positively charged ion per cycle and depolarizing the cell.
Oscillations in membrane potential that surpass the threshold potential triggerectopic beats, and ectopic firing provides the critical premature activation thatinitiates re-entrant activity, in the form of either a single rotor or multiple
rotors or wavelets that sustain fibrillation. Alternatively, repeated rapid firingfrom a focal source can be conducted irregularly through the atrial substrate,
producing fibrillatory activity. The very rapid atrial rate resulting from re-entryor triggered activity in turn abbreviates the effective refractory period (ERP),
entrant activity and promotes AF-which perpetuates re.6Ischaemia,
inflammation, fibrosis, and atrial dilatation also contribute to the AF substrate,and spatial variability of refractoriness is another important determinant ofsustained episodes of AF.10,9
-
8/2/2019 Anti Hypertensive Module
60/71
-
8/2/2019 Anti Hypertensive Module
61/71
Normal cell sodium and potassiumactivities are restored by the Na-K-
ATPase pump, which extrudes thesodium that entered duringdepolarization and pumps in thepotassium that was lost during
repolarization.
-
8/2/2019 Anti Hypertensive Module
62/71
Impulse propagation Once an action potential forms in apatch of membrane (the source), current flows from thispatch to neighboring patches (the sink). Gap junctions are thelow resistance structures that allow ions to flow from one cellto another and, if the current flow is sufficient, to cause
sequential depolarization from cell to cell. The gap junctionsare actually active, opening and closing in response tochanges in pH, calcium, and, at times, voltage. In addition toion flow and gap junction resistance, impulse propagation canalso be affected by the orientation of fibers and of thecollagen matrix in which the fibers reside.
-
8/2/2019 Anti Hypertensive Module
63/71
Fast" tissues may conduct very slowly -declining from meters/sec to millimeters/sec in a number of circumstances. These
include inactivation of sodium channelsinduced by hyperkalemia or ischemia-induced acidosis, direct damage to the cells,or the effect of drugs, particularly
antiarrhythmic drugs.
-
8/2/2019 Anti Hypertensive Module
64/71
Action potential in slow response tissues Thesinoatrial (SA) and atrioventricular (AV) nodesrepresent slow response tissues, which havedifferent properties from the fast response tissues
(show table 1 .)Phase 0 depolarization depends onan inward calcium (not sodium) current via L-typecalcium channels [7.] These channels are selectivefor calcium, have a slower conduction velocity thanthe sodium channels, and take longer to reactivate.
Like the sodium channels, the calcium channels canexist in a resting, open, or inactivated state.
-
8/2/2019 Anti Hypertensive Module
65/71
In some cases, as with tissue damage orchanges in the extracellular milieu, fastresponse tissues can be converted to slowresponse tissues. In this setting, sodiumchannels become inactivated anddepolarization is dependent upon the slow
calcium channels.
-
8/2/2019 Anti Hypertensive Module
66/71
During faster heart rates, less time exists for thedrug to dissociate from the receptor, resulting in anincreased number of blocked channels and
enhanced blockade. These pharmacologic effectsmay cause a progressive decrease in impulseconduction velocity and a widening of the QRScomplex. This property is known as "use-dependency" and is seen most frequently with the
class IC agents, less frequently with the class IAdrugs, and rarely with the class IB agents
-
8/2/2019 Anti Hypertensive Module
67/71
The Class IB drugs lidocaine ,mexiletine ,andtocainide have less prominent sodium channelblocking activity at rest, but effectively block the
sodium channel in depolarized tissues. They tend tobind in the inactivated state (which is induced bydepolarization) and dissociate from the sodiumchannel more rapidly than other Class I drugs. As aresult, they are more effective with tachycardias
than with slow arrhythmias.
-
8/2/2019 Anti Hypertensive Module
68/71
The Class IC drugs flecainideandpropafenone also preferentially bind to the inactivated sodiumchannel. They dissociate slowly from the channel,
resulting in increased effect at more rapid rate, aphenomenon called use-dependence. Thischaracteristic may contribute to the enhancedproarrhythmic effect of these drugs. The Class ICdrugs have little effect on the duration of the action
potential .Propafenonehas significant -blockingactivity.
-
8/2/2019 Anti Hypertensive Module
69/71
Certain arrhythmogenic matrices are common, suchas those induced by ischemia or infarction. In thissetting, a certain effect of a drug becomespredominant and predictable, as with Class Iactivity in ischemia, and a drug classificationappears accurate. However, the major drug effectmay be quite different if a different proarrhythmicmatrix exists. Consider, for example, the differences
indigitalisaction in hypokalemia and hyperkalemia.
-
8/2/2019 Anti Hypertensive Module
70/71
Note that during one cycle of depolarization and repolarization, the sodiumchannel exists in three different states:
Resting.
Active, as the channels open during phase 0 depolarization.
Inactive, which occurs at positive potentials (end of phase 0) and duringmarked depolarization (as during the phase 2 plateau). During recovery, thechannel returns to the resting state.
The resting and inactive states are different physiologically, even though thesodium channel is effectively closed in both settings. In the resting state, thechannel can be opened by the attainment of the threshold potential. In
comparison, the inactive channel cannot be activated until it cycles to theresting state. These different states are important clinically, since someantiarrhythmic drugs (such as the Class IB and IC antiarrhythmic drugs)preferentially bind to inactivated sodium channels (see below.)
-
8/2/2019 Anti Hypertensive Module
71/71
Potential mechanisms by which b-blockersmay lower systemic vascular resistance
Inhibition of b-1 mediated renin release
Inhibition of central autonomic nervoussystem
Resetting of the baroreflex
Effect on prejunctional b-receptors:reduction in noradrenaline release
Increase in vasodilator prostaglandins
top related